8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 12, 2009

Life Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware	000-25317	33-0373077
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5791 Van Allen Way, Carlsbad, CA	92008
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (760) 603-7200

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 — Other Events

          Item 8.01 — Other Events

     On February 12, 2009, Life Technologies Corporation (the “Company”) posted to the Investor Relations section of its website, http://www.lifetechnologies.com, (i) a replay of its investor conference call held on February 12, 2009, relating to the announcement of the Company’s Fourth Quarter and Fiscal Year 2008 results, for which a press release was attached as Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on February 12, 2009, and (ii) a replay of a supplemental investor conference call held on February 12, 2009, relating to the Company’s 2008 Proforma discussion. The replay of the conference calls will be available on the Investor Relations section of the Company’s website for a period of three weeks from February 12, 2009.

     The Company also provided additional answers to certain follow up questions from the investor conference calls by posting a Questions and Answers document to the Investor Relations section of the Company’s website on February 13, 2009. A copy of the Company’s Questions and Answers document, which is attached hereto as Exhibit 99.1, will also be available on the Investor Relations section of the Company’s website for a period of three weeks from February 12, 2009.

Section 9 — Financial Statements and Exhibits

          Item 9.01 — Exhibits

(d) Exhibits

Exhibit 99.1 — Questions and Answers, dated February 13, 2009.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LIFE TECHNOLOGIES CORPORATION (Registrant)
By:	/s/ David F. Hoffmeister
	Chief Financial Officer

Date: February 18, 2009

EX-99.1

Exhibit 99.1

QUESTIONS AND ANSWERS

On Thursday, February 12, 2008, Life Technologies’ provided Q4 and Full Year 2008 financial results via a company press release and subsequent conference call where more financial detail was provided. In addition, the company held a follow up conference call with sell side analysts to answer follow up questions. On this follow up conference call, the company provided supplemental information related to Full Year 2008 earnings and 2009 expectations. A replay of this conference call will be available on the company’s Investor Relations website for three weeks from today.

The company has also provided additional answers to further follow up questions by way of this Question and Answer documented which has both been posted on the Investor Relations portion of the company website.

Q. What was the currency impact on the legacy Invitrogen Cell Culture Systems Division in Q4 2008?

A. The Cell Systems division had a very strong quarter with revenue of $114M, representing 13% organic growth and 17% total revenue growth. Total revenue growth including a positive impact from the CellzDirect acquisitions done in early 2008 and a negative impact from currency. The company initially stated that Cell Systems had a positive impact from currency, but has provided a correction that the impact to growth rates was, in fact, negative from currency. This does not change total company reported results, reported results for the Cell Systems division nor organic growth calculations.

Q. Does the IVGN/AB combined 2008 pro-forma income statement posted on your website reflect AB performance based on a 4/4/5 quarter or calendar quarter?

A. The 2008 pro-forma income statement posted on our website reflects IVGN performance using the calendar system and AB performance using 4/4/5. Moving forward, Life Technologies will utilize a calendar system and as such will have slight differences in comparables resulting from switching the AB business from 4/4/5 to a calendar quarter. Once the exact impact on a quarterly basis is identified, the company will post a revised 2008 pro-forma income statement on the website that reflects both companies performance on a calendar quarter basis prior to the our Q1 2009 earnings call in April. As a result of this change, the revised pro-forma income statement may reflect movement of up to several million dollars in revenue between quarters. The final and revised 2008 pro-forma is expected to be posted by the company’s first quarter earnings call in April.

Q. Why is there more of a difference between the adjusted net income and free cash flow expectations the company provided for 2009?

A. Included in Life Technologies expectations for pro-forma net income are several non-cash charges, including stock option expense, RSUs, and the amortization of loan

fees. In addition, cash taxes will be different than pro-forma taxes given the expenses associated with integrations.

Q. What is the estimate for depreciation in 2009?

A. Approximately $110 — $120 million.

Q. Will you disclose the organic and total revenue growth of each division every quarter?

A. Yes

Q. What is the difference between the revenue of the two standalone companies, Applied Biosystems and Invitrogen, versus the revenue represented in the 2008 pro-forma?

A. Intercompany revenues between the two legacy companies

Q. When the company’s hedging program is complete, approximately what percent of revenues exposed to foreign currencies will be hedged?

A. Approximately 40%

Q. How do I access the replay of the Analyst Q&A call that Life Technologies hosted after the earnings call?

A. The replay of analyst Q&A will be available for three weeks through the IR page of our website or by using the following link: http://ir.lifetechnologies.com/phoenix.zhtml?p=iroleventDetails&c=61498&eventID=2099156.